Biofourmis vs Kepler Vision

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Biofourmis employs 100-500 people, while Kepler Vision has 1-50 employees.

Biofourmis has raised $445M in disclosed funding across 0 known rounds. Kepler Vision's funding history is not publicly available.

Biofourmis holds the higher Awaira Score at 73/100, compared to Kepler Vision's 30/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 43-point gap that reflects meaningful differences in scale or traction.

Biofourmis was founded by Kuldeep Singh in 2015. Kepler Vision was founded by Harro Stokman in 2017. Visit each company's profile on Awaira for a full founder biography.

Biofourmis: Biofourmis develops AI-powered digital therapeutics and remote patient monitoring technology that combines wearable biosensor data with machine learning models to predict clinical deterioration, monitor chronic disease progression, and support clinical trial digital endpoint measurement. The Singapore company platform processes continuous physiological data streams from patients in hospital-at-home programs, enabling earlier clinical intervention and reducing avoidable readmissions for heart failure, oncology, and post-surgical patients.\n\nThe company raised approximately $445 million including a Series D from investors including SoftBank Vision Fund 2, Openspace Ventures, and Mass General Brigham Ventures. Biofourmis has built partnerships with health systems including Brigham and Women Hospital, Guy Hospital, and several major Asian health systems for remote monitoring program deployment, and has entered into pharmaceutical partnerships for using its digital monitoring platform as a clinical trial measurement tool to capture digital endpoints.\n\nBiofourmis competes in the remote patient monitoring and digital therapeutics market against BioIntelliSense, Current Health, and Validic, as well as the monitoring capabilities of established medical device companies including Philips and Masimo that are adding AI analytics to their remote monitoring platforms. The hospital-at-home model, which uses continuous remote monitoring AI to substitute inpatient hospital stays for selected patient populations, represents a significant healthcare cost reduction opportunity that health systems in the US, UK, and Asia are actively piloting. Kepler Vision: Kepler Vision Technologies develops AI fall detection and activity recognition software for elderly care environments, using computer vision models that process video from ceiling-mounted cameras in care facilities to detect falls, assess resident activity patterns, and alert care staff to incidents requiring immediate response. The Amsterdam company platform is designed to operate without wearables or pressure sensors, relying entirely on camera-based analysis to provide unobtrusive monitoring.\n\nThe company is early stage with initial funding from Dutch innovation programmes and care sector partners. Kepler Vision has piloted its Night Nurse product in Dutch residential care facilities, where staff shortages create demand for AI monitoring tools that can maintain safety oversight overnight when staffing ratios are lowest. The platform is designed to comply with European privacy regulations governing personal data processing in care environments, using on-device processing to avoid transmitting identifiable video to cloud services.\n\nKepler Vision operates in the AI elder care market alongside CarePredict, SafelyYou, and camera-based monitoring startups targeting the intersection of computer vision and residential care. The European elder care AI market faces distinct regulatory challenges compared to the US, with GDPR-compliant video monitoring in care facilities requiring explicit consent frameworks and data minimisation approaches. The Netherlands position as a leader in healthcare technology innovation and its advanced residential care infrastructure make it a relevant test market for technology that addresses the growing caregiver shortage across European social care systems.

Biofourmis was founded first in 2015, giving it 2 years of additional market experience. Kepler Vision was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Biofourmis has approximately 100-500 employees, while Kepler Vision has approximately 1-50. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Biofourmis and Kepler Vision are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.